| 1 | 21729281 | Fingolimod modulates microglial activation to augment markers of remyelination. | J Neuroinflammation | 2011 Jul 5 |
1 |
| 2 | 23285242 | The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat. | PLoS One | 2012 |
2 |
| 3 | 23436932 | Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. | J Immunol | 2013 Apr 1 |
1 |
| 4 | 26856814 | The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. | J Neuroinflammation | 2016 Feb 8 |
11 |
| 5 | 27566665 | Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. | J Neuroinflammation | 2016 Aug 26 |
2 |
| 6 | 29205338 | S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset. | Eur J Immunol | 2018 Mar |
2 |
| 7 | 29273968 | In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. | Eur J Clin Pharmacol | 2018 Apr |
12 |
| 8 | 29735753 | Metabolism and Disposition of Siponimod, a Novel Selective S1P<sub>1</sub>/S1P<sub>5</sub> Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism. | Drug Metab Dispos | 2018 Jul |
3 |
| 9 | 30088221 | Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects. | Clin Pharmacokinet | 2019 Mar |
10 |
| 10 | 30105453 | Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. | Eur J Clin Pharmacol | 2018 Dec |
3 |
| 11 | 31144287 | Siponimod: First Global Approval. | Drugs | 2019 Jun |
1 |
| 12 | 31199498 | Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations. | Clin Pharmacol Ther | 2019 Nov |
3 |
| 13 | 31392364 | Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes. | Eur J Clin Pharmacol | 2019 Nov |
3 |
| 14 | 32322257 | Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration. | Front Immunol | 2020 |
19 |
| 15 | 32487716 | A G protein-biased S1P<sub>1</sub> agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers. | Sci Signal | 2020 Jun 2 |
3 |
| 16 | 32488676 | Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages. | Arch Immunol Ther Exp (Warsz) | 2020 Jun 1 |
7 |
| 17 | 32801704 | Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma. | Int J Nanomedicine | 2020 |
5 |
| 18 | 32810927 | A label-free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P<sub>1</sub> agonists. | FEBS Open Bio | 2020 Oct |
1 |
| 19 | 33058113 | Secondary progressive multiple sclerosis - from neuropathology to definition and effective treatment. | Neurol Neurochir Pol | 2020 |
1 |
| 20 | 33108633 | Siponimod: A Review in Secondary Progressive Multiple Sclerosis. | CNS Drugs | 2020 Nov |
2 |
| 21 | 33577891 | Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function. | Biochem Pharmacol | 2021 Apr |
4 |
| 22 | 33797705 | Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. | CNS Drugs | 2021 Apr |
2 |
| 23 | 34059068 | The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer. | J Nanobiotechnology | 2021 May 31 |
18 |
| 24 | 34109627 | PharmVar GeneFocus: CYP2C9. | Clin Pharmacol Ther | 2021 Sep |
1 |
| 25 | 34340305 | Identification of Potential Inhibitors against Epstein-Barr Virus Nuclear Antigen 1 (EBNA1): An Insight from Docking and Molecular Dynamic Simulations. | ACS Chem Neurosci | 2021 Aug 18 |
3 |
| 26 | 34599741 | Decreased Astrocytic CCL2 Accounts for BAF-312 Effect on PBMCs Transendothelial Migration Through a Blood Brain Barrier in Vitro Model. | J Neuroimmune Pharmacol | 2021 Oct 2 |
1 |
| 27 | 34777855 | Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights. | Mult Scler J Exp Transl Clin | 2021 Oct |
4 |
| 28 | 34911793 | Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis. | Neurol Neuroimmunol Neuroinflamm | 2022 Jan |
2 |
| 29 | 34937912 | Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism. | Nat Chem Biol | 2022 Mar |
3 |
| 30 | 35136060 | Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate. | Nat Commun | 2022 Feb 8 |
1 |
| 31 | 35354603 | Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models. | Neurol Neuroimmunol Neuroinflamm | 2022 May |
1 |
| 32 | 35426132 | The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin. | Clin Pharmacol Ther | 2022 Jul |
1 |
| 33 | 35620290 | Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials. | Front Pharmacol | 2022 |
1 |